In the new study, Phospha E lowered LDL cholesterol concentrations in blood by up to 44 per cent and triglycerides by up to 51 per cent in mice fed normal diets.
The earlier study had shown similar results in mice fed a high cholesterol diet for eight weeks.
In both studies, a comparison with a normal vitamin E showed no significant benefit.
Phosphagenics has developed an enhanced form of vitamin E, called Phospha E. It has been licensed to US firm Zila, which markets the product in the US, Canada and Indonesia as Ester-E. It is looking for European marketing approval.
The new study also showed that when fed high cholesterol diets, mice given Phospha E had a 58 per cent lower plaque formation in the aorta. Again, regular vitamin E had no significant effect on plaque formation.
The animal model chosen for the trials is commonly used in cardiovascular research as it mimics many of the properties observed clinically in humans.
"Based on these animal studies, as well as earlier in vitro studies, we are confident in the potential of Phospha E to support cardiovascular health in humans," said Dr Esra Ogru, the firm's director of R&D.
She added that Phosphagenics is planning to start clinical trials in humans to provide further support for the product's cardiovascular benefits.
